Varian Medical acquires Mobius Medical Systems

Varian Medical (NYSE:VAR) said yesterday it bought radiation oncology quality assurance software maker Mobius Medical Systems for an undisclosed amount. The Palo Alto, Calif.-based company said the acquisition will be beneficial to its portfolio of patient treatment plan QA and machine QA technologies, and that integration of the Mobius’ technologies will enable advanced QA processes to be “seamlessly combined into treatment workflows.” Mobius’ QA software is currently in use at over 1,000 sites globally, and includes the Mobius3D dose verification and IMRT/VMAT treatment delivery system, the company said. “Varian has a long history of providing high-quality QA for its products and the treatments they deliver. Varian places high value on the market-leading Mobius QA products, including Mobius3D and DoseLab, and is dedicated to expanding their global reach. The two companies have similar cultures with deep commitments to enabling quality cancer care for patients around the globe,” Varian oncology systems biz prez Kolleen Kennedy said in a press release. The acquisition is the second for the company in less than two weeks after it agreed to pay nearly $1.3 billion for Australia’s Sirtex Medical (ASX:SRX) and its anti-cancer microspheres. The post Varian Medical acquires Mobius Medical Systems appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Mergers & Acquisitions Software / IT mobiusmedicalsystems Varian Medical Systems Source Type: news

Related Links:

We examined whether the dose –volume histogram obtained from the tongue surface model correlates with mucositis severity, and whether it is useful for predicting acute radiation tongue mucositis in patients with head and neck cancer treated with intensity-modulated radiation therapy. Thirty-six patients who received intensity -modulated radiation therapy for head and neck cancer were analysed for acute radiation tongue mucositis according to the Common Terminology Criteria for Adverse Events, version 4.0, as well as the Radiation Therapy Oncology Group scoring systems.
Source: International Journal of Oral and Maxillofacial Surgery - Category: ENT & OMF Authors: Tags: Research Paper Source Type: research
Abstract The aim of the present study was to compare radiation dose received by thyroid gland using different radiotherapy (RT) techniques with or without thyroid dose constraint (DC) for breast cancer patients. Computerized tomography (CT) image sets for 10 patients with breast cancer were selected. All patients were treated originally with opposite tangential field-in field (FinF) for the chest wall and anteroposterior fields for the ipsilateral supraclavicular field. The thyroid gland was not contoured on the CT images at the time of the original scheduled treatment. Four new treatment plans were created for ea...
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Tags: J Appl Clin Med Phys Source Type: research
CONCLUSION: This regimen demonstrated promising activity. Toxicity was significant, with seven study-related deaths leading to closure after stage 1. All postoperative deaths were due to ARDS. This regimen is not recommended. IMPLICATIONS FOR PRACTICE: Esophageal cancer is a disease with a high death rate. The current treatment involves giving chemotherapy plus radiation followed by surgery, but this cures only a quarter of patients. In order to improve survival, better treatments are needed. This trial evaluated the addition of a novel drug, cetuximab, to chemotherapy plus radiation. Unfortunately, the side effects w...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
The aim of this study was to analyze the impact of different radiation techniques on the long-term incidence of osteoradionecrosis in head and neck cancer. Risk factors and the occurrence of osteoradionecrosis were analyzed in a retrospective, comparative, observational study. Medical files and radiological images of 109 patients treated with primary intensity-modulated radiation therapy (IMRT) and 129 patients treated with primary three-dimensional conformal radiotherapy (3D-CRT) were evaluated.
Source: International Journal of Oral and Maxillofacial Surgery - Category: ENT & OMF Authors: Tags: Clinical Paper Source Type: research
Condition:   Esophageal Cancer Interventions:   Drug: Oxaliplatin;   Drug: S-1 capsule;   Radiation: Intensity modulated radiotherapy (IMRT) Sponsor:   Zhejiang Provincial People’s Hospital Recruiting
Source: - Category: Research Source Type: clinical trials
Conclusions: In naTC patients who have pT3-4, pN+ disease or R1-2 resection, pEBRT improved LRF. Limited-field IMRT is preferred.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Conclusions: The clinical results suggest that IMRT concurrent with chemotherapy isan effective treatment with acceptable toxicity for advanced cervical cancer with positive lymph nodes.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionPre ‐EBV DNA could be a useful tool to guide individualized treatment for stage II‐III NPC patients. Additional CCT to IMRT improved the survival for patients with high pre‐EBV DNA, while those with low pre‐EBV DNA could not.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
The purpose of this study was to investigate the dosimetric impact of weight loss in head and neck (H&N) patients and examine the effectiveness of adaptive planning. Data was collected from 22 H&N cancer patients who experienced weight loss during their course of radiotherapy. The robustness of Intensity Modulated Radiation Therapy (IMRT) and Volumetric Modulated Arc Therapy (VMAT) treatment plans were compared including the potential need for replanning. The dosimetric impact of weight loss was evaluated by calculating a verification plan for each patient on an assessment CT scan taken during the course of treatment.
Source: Medical Dosimetry - Category: Radiology Authors: Source Type: research
Conclusions: The intensified treatment paradigm of XELOX concurrent chemoradiation followed by one cycle of consolidation chemotherapy was well tolerated in our cohort and provided a promising long-term oncologic outcome, which warranted further investigation in a randomize trails.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
More News: Cancer | Cancer & Oncology | Intensity-Modulated Radiation Therapy | Mergers and Aquisitions